Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Study shows mild cognitive impairment affects men more than women

A new study shows that mild cognitive impairment (MCI) may affect more men than women. The research is published in the September 7, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

7 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

A research clinic for multiple sclerosis patients is being set up with a -10 million donation from the author J K Rowling.The Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh will place patients at the heart of research to improve outcomes for multiple sclerosis sufferers.

2 Sep 2010

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

University of British Columbia researchers have led the development of a new "toolbox of MiniPromoters" for research and future therapies on brain, spinal cord and eye function.

31 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

People with insulin resistance and type 2 diabetes appear to be at an increased risk of developing plaques in the brain that are associated with Alzheimer's disease, according to new research published in the August 25, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

26 Aug 2010

Scientists discover Magnetic Resonance Spectroscopy can rapidly diagnose degenerative disorders

Magnetic Resonance Spectroscopy can distinguish between neurological diseases in patients without clear symptoms.A team of American scientists claim that a new method of testing for neurological diseases could provide doctors with a rapid and non-invasively method of diagnosing degenerative disorders.

25 Aug 2010

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals, Inc.,a leading RNAi therapeutics company, announced today that it will make a total of 16 oral presentations at the American Chemical Society (ACS) Fall 2010 240th National Meeting & Exposition being held in Boston, Mass. from August 22-26, 2010.

24 Aug 2010

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Raptor Pharmaceutical Corp.,provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

24 Aug 2010

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.

24 Aug 2010

New avenues for stem cell research

According to researchers at the University of NSW a new way has been found to generate stem cells from human skin - known as induced pluripotent stem (iPS) cells. A paper outlining the breakthrough was published this week in the US-based international online journal PLoS One.

19 Aug 2010

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Neuralstem, Inc. announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course. This patent describes methods of culturing and expanding neural stem cells.

19 Aug 2010

MMV joins Pool for Open Innovation against neglected tropical diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).

17 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Research identifies abnormal huntingtin protein critical for mitosis and cell fate determination

New research finds that a protein that is often mutated in Huntington's disease (HD) plays an unexpected role in the process of neurogenesis. The research, published by Cell Press in the August 12 issue of the journal Neuron, provides new insight into HD pathology and has even broader implications for human health and disease.

12 Aug 2010

Common soluble proteins become insoluble and form aggregates while aging: Study

In neurodegenerative diseases, clumps of insoluble proteins appear in patients' brains. These aggregates contain proteins that are unique to each disease, such as amyloid beta in Alzheimer's disease, but they are intertwined with small amounts of many other insoluble proteins that are normally present in a soluble form in healthy young individuals. For years, these other proteins were thought to be accidental inclusions in the aggregates, much as a sea turtle might be caught in a net of fish.Now, in a surprising new finding, researchers at the University of California, San Francisco, report that many of the proteins present as minor components of disease aggregates actually clump together as a normal part of aging in healthy individuals.

11 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Raptor Pharmaceutical to raise $15 million through PIPE financing

Raptor Pharmaceutical Corp., announced it has entered into a securities purchase agreement in connection with a private placement, or PIPE financing. Upon the closing of the PIPE financing, Raptor will receive gross proceeds of approximately $15 million resulting from the sale of 4,897,614 units at a purchase price of $3.075 per unit.

10 Aug 2010

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation, Inc. today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

A newly discovered molecular mechanism helps control the amount and effectiveness of a substance that mimics an active ingredient in marijuana, but that is produced by the body's own nerve cells.

7 Aug 2010

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Study shows mild cognitive impairment affects men more than women

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

Scientists discover Magnetic Resonance Spectroscopy can rapidly diagnose degenerative disorders

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Raptor Pharmaceutical updates on cysteamine bitartrate Phase 3 clinical trial in cystinosis patients

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

New avenues for stem cell research

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

MMV joins Pool for Open Innovation against neglected tropical diseases

Neurologix second-quarter net loss increases to $4.5 million

Research identifies abnormal huntingtin protein critical for mitosis and cell fate determination

Common soluble proteins become insoluble and form aggregates while aging: Study

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Raptor Pharmaceutical to raise $15 million through PIPE financing

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in